Objectives: To assess the prognostic value of Fluorine 18-labeled fluorodeoxyglucose [F]FDG, gallium 68-labeled fibroblast-activation protein inhibitor-04 [Ga]Ga-FAPI-04, C-acetate in hepatocellular carcinoma (HCC) and evaluate the potential usefulness and advantages of different combinations for accurate diagnosis.

Materials And Methods: Thirty-six patients with suspected hepatic masses were prospectively enrolled from May 2021 to September 2022 and underwent [F]FDG, [Ga]Ga-FAPI-04, and C-acetate PET/CT scans before surgery. PET/CT results and histopathologic examinations were independently interpreted by two radiologists and pathologists, respectively. Kaplan-Meier overall survival curves were calculated and the sensitivity among [F]FDG, C-acetate, [Ga]Ga-FAPI-04, and different combinations were compared.

Results: Of the 36 included patients (mean age, 59 years ± 10 (standard deviation)), 29 were diagnosed with HCC, four with non-HCC malignant tumors, and three with benign tumors. Patients with HCC lesions negative for C-acetate or [Ga]Ga-FAPI-04 exhibited poorer overall survival. Out of 36 patients, 44 HCC lesions were detected. The dual-tracer [Ga]Ga-FAPI-04/C-acetate exhibited the highest sensitivity (39 of 44 lesions (88.6%)) among all schemes. HCC lesions with higher histological grade and microvascular invasion (MVI) showed higher maximum standardized uptake value (SUV) and tumor-to-background ratio (TBR) of [F]FDG, but no evidence of significant differences was found in [Ga]Ga-FAPI-04 and C-acetate PET/CT. Higher expression of fibroblast activation protein (FAP) showed higher uptake of [Ga]Ga-FAPI-04 and [F]FDG.

Conclusion: [Ga]Ga-FAPI-04 and C-acetate PET/CT exhibited good predictive value for HCC patients, with their combination showing the highest sensitivity for HCC detection, suggesting potential for improved diagnostic protocols.

Key Points: Question What are the prognostic and diagnostic values of PET/CT tracers, including [F]FDG, [Ga]FAPI-04, and C-acetate? Findings Hepatocellular carcinoma, with differing findings across [F]FDG, [Ga]GaFAPI-04, and C-acetate PET/CT, showed varied prognoses; [Ga]GaFAPI-04 and C-acetate combined offered the highest detection sensitivity. Clinical relevance Evaluating the prognostic value and diagnostic efficacy of different tracer combinations in patients with hepatocellular carcinoma helps to guide the optimal selection of tracers in clinical practice.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-025-11352-3DOI Listing

Publication Analysis

Top Keywords

hepatocellular carcinoma
16
[ga]ga-fapi-04 c-acetate
16
c-acetate pet/ct
16
prognostic diagnostic
12
c-acetate [ga]ga-fapi-04
12
hcc lesions
12
c-acetate
9
[f]fdg c-acetate
8
[ga]ga-fapi-04
8
patients hcc
8

Similar Publications

Purpose: The present work focused on assessing whether hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and tislelizumab was safe and effective on advanced hepatocellular carcinoma (HCC) showing high tumor burden.

Methods: In the present multicenter retrospective study, treatment-naive advanced HCC patients (BCLC stage C) showing high tumor burden (maximum diameter of intrahepatic lesion beyond 7 cm) treated with lenvatinib and tislelizumab with or without HAIC were reviewed for eligibility from June 2020 to June 2023. Baseline differences between groups were mitigated by propensity score matching (PSM).

View Article and Find Full Text PDF

Serum proteomic and metabolomic profiling of hepatocellular carcinoma patients co-infected with .

Front Immunol

January 2025

Key Laboratory of Longevity and Aging-related Diseases of Chinese Ministry of Education, Guangxi Medical University, Nanning, China.

Background: () infection is a significant risk factor for hepatocellular carcinoma (HCC), yet its underlying mechanisms remain poorly understood. This study aimed to investigate the impact of infection on the serum proteomic and metabolomic profiling of HCC patients, focusing on the potential mechanisms.

Method: A retrospective clinical analysis was conducted on 1121 HCC patients, comparing those with and without infection.

View Article and Find Full Text PDF

Background: Hepatocellular carcinoma (LIHC) poses a significant health challenge worldwide, primarily due to late-stage diagnosis and the limited effectiveness of current therapies. Cancer stem cells are known to play a role in tumor development, metastasis, and resistance to treatment. A thorough understanding of genes associated with stem cells is crucial for improving the diagnostic precision of LIHC and for the advancement of effective immunotherapy approaches.

View Article and Find Full Text PDF

Purpose: This study aimed to investigate whether tumor-associated lymphatic vessel density (LVD) could predict the survival of patients with hepato-biliary-pancreatic (HBP) cancers after radical resection.

Methods: A systematic search was conducted using PubMed, Embase, and Cochrane Library from the inception to July 31, 2024 for literature that reported the role of LVD in overall survival (OS) and recurrence-free survival (RFS) of patients with HBP cancers after radical resection.

Results: Ten studies with 761 patients were included for the meta-analysis.

View Article and Find Full Text PDF

Transplant oncology and anti-cancer immunosuppressants.

Front Immunol

January 2025

Tianjin Organ Transplantation Research Center, Tianjin First Central Hospital, Nankai University School of Medicine, Tianjin, China.

Organ transplantation is a life-saving intervention that enhances the quality of life for patients with end-stage organ failure. However, long-term immunosuppressive therapy is required to prevent allogeneic graft rejection, which inadvertently elevates the risk of post-transplant malignancies, especially for liver transplant recipients with a prior history of liver cancer. In response, the emerging field of transplant oncology integrates principles from oncology and immunology to improve outcomes for patients at high risk of tumor occurrence or recurrence following transplantation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!